Kamada Ltd. (NASDAQ:KMDA) Announces — Dividend of $0.20

Kamada Ltd. (NASDAQ:KMDA) announced a — dividend on Wednesday, March 5th, NASDAQ Dividends reports. Investors of record on Monday, March 17th will be given a dividend of 0.20 per share by the biotechnology company on Monday, April 7th. The ex-dividend date is Monday, March 17th.

Kamada Trading Down 0.7 %

NASDAQ KMDA opened at $7.18 on Friday. The company has a fifty day simple moving average of $7.22 and a 200 day simple moving average of $6.20. The company has a market cap of $412.71 million, a P/E ratio of 25.64, a P/E/G ratio of 0.97 and a beta of 0.97. Kamada has a 1 year low of $4.74 and a 1 year high of $9.15.

Analyst Ratings Changes

Several analysts recently issued reports on KMDA shares. StockNews.com raised shares of Kamada from a “buy” rating to a “strong-buy” rating in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Kamada in a report on Thursday, March 6th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.